Selvita – accelerating drug discovery

Selvita is a biotech company offering drug discovery support at every step of the process, from the early discovery phase up to preclinical research. Selvita delivers a comprehensive panel of solutions to accelerate and decrease the cost of the introduction of new drugs to the market.

Selvita – accelerating drug discovery


Selvita is an independent integrated drug discovery provider, offering services ranging from medicinal chemistry, computational chemistry, through chemical development and custom synthesis, to preclinical in vitro research, all done in-house. Selvita’s mission is to propose a comprehensive panel of products and solutions in order to accelerate and lower the cost of the introduction of new drugs to the market. Selvita offers integrated drug discovery projects, including in silico drug design, synthesis of a target-focused library, SAR and ADME-driven lead optimization and toxicity prediction, complex preclinical in vitro development, etc… Selvita also proposes chemistry services (contract synthesis, synthesis pathway design and optimization, synthesis scale-up, stability studies, impurity profiles, etc…). Furthermore, Selvita provides advanced protein modeling solutions based on its proprietary protein modeling platform. Selvita also develops its own innovative drugs, which originate from research at Polish universities and later commercializes them with partners from the pharmaceutical industry. Current projects are dedicated to oncology, central nervous system and autoimmune diseases. Selvita has currently several projects at early or late discovery stage and is expected to move its first candidates to the clinic in 2015.

Selvita is based in Kraków (Poland). Supervisory Boardis composed by Piotr Romanowski, Tadeusz Wesołowski, Rafał Chwast, Adam Przewiezlikowski and Adam Dubin. Management Team is composed by Paweł Przewięźlikowski, Bogusław Sieczkowski, Krzysztof Brzózka, Mirosława Zydroń, Miłosz Gruca and Sebastian Kwaśny. And Scientific Advisory Board is composed by Adam Dubin, Andrzej Pilc, Bożena Kamińska, Przemysław Juszczyński and Jerzy Ostrowski. Selvita possesses the Good Laboratory Practice (GLP) certificate, as well as the Polish Main Pharmaceutical Inspectorate accreditation. Selvita is also the majority shareholder of BioCentrum, which provides preclinical ADMET services, and biopharmaceutical development services.

More about Selvita:

Selvita – drug discovery support – accelerating drug discovery

Selvita – drug discovery – drug discovery provider – medicinal chemistry – computational chemistry – through chemical development – custom synthesis – preclinical in vitro research – in silico drug design – in silico – drug design – toxicity prediction – synthesis scale-up – stability studies – impurity profiles – oncology – central nervous system – autoimmune diseases – Piotr Romanowski – Tadeusz Wesołowski – Rafał Chwast – Adam Przewiezlikowski – Adam Dubin – Paweł Przewięźlikowski – Bogusław Sieczkowski – Krzysztof Brzózka – Mirosława Zydroń – Miłosz Gruca – Sebastian Kwaśny – Adam Dubin – Andrzej Pilc – Bożena Kamińska – Przemysław Juszczyński – Jerzy Ostrowski